TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Short Interest Update

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 172,000 shares, an increase of 20.5% from the October 15th total of 142,700 shares. Approximately 5.6% of the shares of the stock are sold short. Based on an average daily volume of 71,600 shares, the days-to-cover ratio is presently 2.4 days.

TFF Pharmaceuticals Price Performance

Shares of TFFP stock traded down $1.22 on Friday, hitting $0.38. 9,167,990 shares of the company’s stock were exchanged, compared to its average volume of 94,204. The company has a 50 day moving average of $2.02 and a 200 day moving average of $1.99. The stock has a market cap of $1.31 million, a P/E ratio of -0.05 and a beta of 1.32. TFF Pharmaceuticals has a 12 month low of $0.27 and a 12 month high of $11.00.

TFF Pharmaceuticals (NASDAQ:TFFP) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($1.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.70) by $0.48. The company had revenue of $0.65 million for the quarter, compared to analyst estimates of $0.15 million. TFF Pharmaceuticals had a negative net margin of 1,612.73% and a negative return on equity of 225.15%. Sell-side analysts predict that TFF Pharmaceuticals will post -4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TFF Pharmaceuticals stock. Armistice Capital LLC bought a new position in TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 185,695 shares of the company’s stock, valued at approximately $308,000. Armistice Capital LLC owned approximately 5.99% of TFF Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 15.25% of the company’s stock.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.